Skip to Main Content

Oncolytic

Animal-origin-free proteins for every step of Oncolytic manufacturing.

From producer cell expansion to frozen storage, chemically defined VERO media and recombinant albumin, transferrin and lactoferrin remove serum and plasma-derived albumin from a live virus product.

Where InVitria proteins fit in Oncolytic Manufacturing

An oncolytic virus is a live, replicating product with no inactivation step, so raw material purity at every step carries into the dose. Serum brings lot variability and adventitious agent risk to expansion and infection, and human or bovine serum albumin follows the virus downstream. Defined, animal-origin-free proteins lower that step by step, from a chemically defined medium upstream to recombinant albumin against surface loss and freeze-thaw stress.

Where our products fit

The Oncolytic workflow, step by step.

Select a step to see what it involves and which InVitria® products replace animal-derived inputs there.

Producer Cell Expansion

Expand Vero or HEK293 producer cells to infection-ready density, with a chemically defined, animal-origin-free medium supporting consistent growth ahead of a live, replication-competent product.

Overview

Producer cell expansion grows the packaging or producer cell line, commonly Vero or HEK293, from a working cell bank to the density needed for viral infection. HEK293 lines often serve as complementing cells, supplying viral genes deleted from a replication-defective backbone in trans; Vero supports replication-competent constructs directly.

Because the finished product is a live, replication-competent or conditionally replicating virus rather than an inactivated antigen, raw material purity at this step carries directly into the safety profile of the dose, with no inactivation step downstream to add a safety margin.

A chemically defined, animal-origin-free complete medium removes serum-associated adventitious agent risk and lot variability from expansion, supporting a producer cell population whose purity is not diluted downstream.

Functions

Complete Media

Producer cell expansion for a live, replication-competent virus product carries raw material risk forward with no inactivation step to add a safety margin downstream. Serum is compositionally variable and a documented adventitious agent route. A chemically defined, animal-origin-free complete medium supports consistent doubling time and confluency in 2D and 3D formats while keeping this risk out of the process from the start.

Recommendation
OptiVERO®

Chemically defined, blood-free complete medium for VERO cell expansion and virus production in 2D flask and 3D microcarrier formats.

Commonly replaces
Fetal bovine serum (FBS)-supplemented growth medium for producer cell expansion.

Vero Growth Signaling

Vero producer cells expanded in serum-free medium depend on a defined mitogen to reach infection-ready density, and EGF is that mitogen. EGFR signaling drives Vero proliferation and sets the doubling time that determines when the producer population is ready for infection with a replication-competent construct. In serum-free OptiVERO, OptiKine EGF drove 11.5-fold Vero expansion in 3 days against 3.9-fold with no EGF. For a live virus product with no downstream inactivation step, the EGF source carries directly into the safety profile of the dose: an animal-origin-free EGF free of microbial fermentation and mammalian cells keeps endotoxin, host-cell protein, and adventitious-agent risk out of the producer culture from the start.

Recommendation
OptiKine™ EGF

Recombinant human Epidermal Growth Factor from an animal-origin-free expression system, for epithelial, keratinocyte, and organoid culture and stem-cell proliferation.

Commonly replaces
E. coli- or mammalian-cell-derived recombinant human EGF, typically lyophilized, and serum used as the growth-factor source in producer cell expansion medium.

Producer Cell Growth & Viability

Mammalian producer cell lines must reach healthy density before infection. Lactoferrin can support producer-cell proliferation and viability in serum-free expansion in mammalian production systems.

Recommendation
Lacromin®

Recombinant human holo-lactoferrin, an iron-saturated lyophilized powder for serum-free and chemically defined cell culture media.

Commonly replaces
Bovine lactoferrin; serum in producer-cell media.

Viral Infection & Propagation

Infect Vero or HEK293 cells with the oncolytic construct and propagate to the high titer clinical dosing requires, with defined albumin and transferrin supporting cell metabolism in place of serum.

Overview

Viral infection introduces the oncolytic construct, or a helper virus for replication-defective backbones, to producer cells at a defined multiplicity of infection. Cells are then incubated through the propagation window to peak titer, monitored by cytopathic effect or plaque assay.

Oncolytic virus clinical doses are large, commonly 10⁹ to 10¹¹ viral particles per administration, placing sustained metabolic and oxidative demand on producer cells across an infection cycle typically run in reduced-serum or serum-free medium.

Recombinant transferrin supplies iron as a protein-bound complex rather than free ion, and defined albumin buffers cells against the handling and metabolic stress of high-titer propagation, supporting cell health through the window that sets final virus yield.

Functions

Producer Cell Support

High-titer oncolytic virus production sustains producer cells through an extended, metabolically demanding propagation window run in reduced-serum or serum-free medium. A carrier protein in the medium supplies the buffering, lipid transport, and antioxidant capacity serum otherwise provides, supporting cell viability through the window that sets final virus yield.

Recommendation
Cellastim® S

Cell culture recombinant albumin to enhance proliferation in serum free and chemically defined cell culture. Lyophilized.

Commonly replaces
Serum-derived albumin supplementation in infection/propagation medium.

Harvest & Lysis

Release intracellular virus from producer cells by freeze-thaw, mechanical, or chemical lysis ahead of clarification.

Overview

Many oncolytic viruses, including HSV-1 and adenovirus-based constructs, are highly cell-associated: most infectious particles stay intracellular through propagation rather than budding into the supernatant. Harvest therefore requires active lysis to liberate virus, using repeated freeze-thaw cycling, mechanical disruption such as microfluidization or homogenization, or mild detergent-based chemical lysis.

Mammalian producer cells have no cell wall, only a lipid plasma membrane, so lysis works by physically or osmotically disrupting that membrane rather than by enzymatically degrading a wall structure. This differs mechanistically from bacterial lysis, where a cell wall-degrading enzyme is the standard tool.

The resulting crude lysate, a mixture of released virus, nuclear and membrane debris, and host cell protein and DNA, proceeds directly to clarification. Lysis acts on the cell membrane and does not require a process aid protein.

Nuclease Treatment

Treat the lysate with endonuclease (Benzonase) to clear host-cell nucleic acids and lower viscosity before clarification and capture.

Overview

Oncolytic-virus lysates carry high host-cell chromatin/DNA and are viscous. Endonuclease (Benzonase) digestion after lysis clears host-cell nucleic acids to meet residual-DNA limits and reduces viscosity, improving clarification and chromatography. Magnesium is supplemented as cofactor; digestion is timed and carried through clarification.

Clarification

Clarify the crude lysate by centrifugation or depth filtration, with defined albumin limiting virus loss to filter and vessel surfaces during recovery.

Overview

Clarification separates released virus from the nuclear fragments, membrane debris, and host cell protein and DNA present in crude cell lysate, typically by low-speed centrifugation followed by depth filtration. The debris load from a lysed producer cell population is higher than from a secreted-product harvest, raising the risk of filter fouling and surface-mediated virus loss.

At the low protein and particle concentrations typical of clarified lysate, nonspecific virus adsorption to filter media, tubing, and vessel surfaces can remove a meaningful fraction of total virus before purification begins.

A carrier protein added to clarification buffers competes for these nonspecific binding sites, limiting virus adsorption and supporting yield recovery into the purification train.

Functions

Anti-Adsorption

Clarified lysate is dilute and carries a higher debris load than a typical secreted-product harvest, and virus particles adsorb nonspecifically to the filter media, tubing, and vessel surfaces they contact during clarification. A carrier protein occupies these binding sites ahead of the virus, limiting adsorptive loss and preserving recoverable titer.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Exbumin®

Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.

Commonly replaces
Process-supplied HSA used to limit virus adsorption during clarification.

Capture & Polish Chromatography

Purify oncolytic virus by chromatography and TFF to meet host cell DNA and protein clearance specifications, with defined albumin limiting virus loss to resin and membrane surfaces.

Overview

Purification removes host cell protein and DNA, media residuals, and non-target particles from clarified lysate using ion-exchange or multimodal chromatography and tangential flow filtration for intermediate concentration. Because the product is a live, replication-competent virus, residual host cell DNA is held to strict specification, commonly on the order of nanograms per dose.

Each chromatography and filtration step dilutes the virus stream and passes it over large resin or membrane surface area. Enveloped constructs such as HSV-1 and vaccinia, and large icosahedral capsids such as adenovirus, are both prone to shear and surface-mediated loss at these lower concentrations.

A carrier protein in purification buffers competes for nonspecific binding sites on resin and membranes, protecting recovery through each step on the way to a purified virus pool.

Functions

Anti-Adsorption

Chromatography and TFF steps dilute the virus stream and expose enveloped or capsid surfaces to large resin and membrane areas, where nonspecific adsorption removes virus disproportionately from dilute pools. A carrier protein in purification buffers occupies these sites, protecting recovery as virus moves through each purification step.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Exbumin®

Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.

Commonly replaces
Site-supplied HSA/BSA carrier protein in purification buffers.

Concentration & Buffer Exchange (TFF / UF-DF)

Concentrate purified virus to target dose titer and exchange into formulation buffer by TFF, with defined albumin limiting interfacial stress on the viral envelope and capsid.

Overview

Concentration and buffer exchange use tangential flow filtration to raise purified virus to the high particle concentration clinical dosing requires, commonly 10⁹ to 10¹¹ viral particles per mL for intratumoral or intravenous formats, while diafiltering into formulation-compatible buffer.

At high particle density, viral surfaces are subject to increased self-interaction as well as membrane shear and air-liquid interfacial stress during TFF, raising the risk of aggregation and loss of infectivity for enveloped constructs in particular.

A surface-active carrier protein preferentially occupies these interfaces, limiting viral surface exposure to interfacial stress and supporting particle integrity through concentration and buffer exchange.

Functions

Vector Protection

Concentrating virus to clinical dosing titer increases particle density and exposes viral envelope and capsid surfaces to membrane shear and air-liquid interfacial stress during TFF, raising aggregation risk. A surface-active carrier protein preferentially occupies these interfaces ahead of the virus, limiting its exposure to interfacial stress during concentration and diafiltration.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Exbumin®

Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.

Commonly replaces
Serum albumin included as a stabilizing excipient during UF/DF.

Sterile Fill & Formulation

Formulate concentrated virus with stabilizing excipients and aseptically fill into final containers, since many oncolytic constructs are too large for terminal sterile filtration.

Overview

Sterile fill and formulation combines concentrated virus with a formulation buffer, typically including a sugar cryoprotectant such as sucrose or trehalose and a stabilizing carrier protein, then dispenses the product into vials or syringes under aseptic processing.

Several oncolytic platforms, including vaccinia (roughly 360 nm) and HSV-1, exceed the pore size of standard 0.2 micron sterile-grade filters, so bioburden control relies on aseptic processing through upstream sterile-filtered components rather than terminal filtration of the final virus pool.

A stabilizing carrier protein in the formulation buffer protects virus structure through filling and dispensing, at the low absolute concentration typical of finished formulated product.

Note: large oncolytic viruses (e.g., vaccinia, HSV) exceed the 0.22 um sterilizing-filter cutoff and are processed by closed aseptic manufacturing rather than terminal sterile filtration.

Functions

Formulation Stabilization

Finished virus product is formulated at low absolute concentration relative to the excipient load needed to stabilize it through aseptic filling, and several oncolytic platforms are too large for terminal sterile filtration, leaving formulation stability as a primary safeguard. An excipient protein in the formulation buffer protects viral structure through fill-line handling.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Exbumin®

Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.

Commonly replaces
Human serum albumin (HSA) used as a formulation stabilizing excipient.

Cryopreservation & Storage

Store the filled product frozen, commonly at -60 to -90 degrees C, with defined albumin buffering the viral envelope against freeze-thaw stress over shelf life.

Overview

Cryopreservation and storage hold the finished oncolytic virus product frozen, commonly in the -60 to -90 degree C range rather than simple refrigeration, reflecting the greater freeze-thaw and storage sensitivity of enveloped and complex viral particles compared with small-molecule or protein products.

Enveloped constructs such as HSV-1 and vaccinia are particularly vulnerable to freeze-thaw cycling: ice crystal formation and the resulting increase in local solute concentration can disrupt the lipid envelope and reduce infectious titer.

A cryoprotectant carrier protein in the formulation buffer buffers virus against this freeze-thaw stress and limits contact with the container surface, supporting infectious titer through the labeled frozen storage period.

Functions

Storage Stabilization

Frozen storage exposes enveloped virus to freeze-thaw cycling, where ice crystal formation and rising local solute concentration can disrupt the lipid envelope and reduce infectious titer. A cryoprotectant carrier protein in the formulation buffer buffers virus against this stress and limits container-surface adsorption, supporting titer through the labeled storage period.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Exbumin®

Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.

Commonly replaces
HSA-based cryoprotectant in storage/formulation buffer.